Study Title
AALL15P1: A Groupwide Pilot Study to Test the Tolerability and Biologic Activity of the Addition of Azacitidine (NSC# 102816) to Chemotherapy in Infants With Acute Lymphoblastic Leukemia (ALL) and KMT2A (MLL) Gene Rearrangement
Protocol ID
AALL15P1
Condition/s
Acute Leukemia of Ambiguous Lineage
B Acute Lymphoblastic Leukemia
Mixed Phenotype Acute Leukemia
B Acute Lymphoblastic Leukemia
Mixed Phenotype Acute Leukemia
Diagnosis Stage
Newly diagnosed
Location
WA
Sponsor
National Cancer Institute (NCI)
Links
Trial Status
Temporarily Closed
Sites
Perth Children's Hospital
Study Type
Treatment
Phase
Phase 2
Age Eligibility
up to 364 days
International registry ID's
NCT02828358
| Study Title | AALL15P1: A Groupwide Pilot Study to Test the Tolerability and Biologic Activity of the Addition of Azacitidine (NSC# 102816) to Chemotherapy in Infants With Acute Lymphoblastic Leukemia (ALL) and KMT2A (MLL) Gene Rearrangement |
|---|---|
| Protocol ID | AALL15P1 |
| Disease (Sub Disease) | Acute Leukemia of Ambiguous Lineage B Acute Lymphoblastic Leukemia Mixed Phenotype Acute Leukemia |
| Diagnosis Stage | Newly diagnosed |
| Location | WA |
| Sponsor | National Cancer Institute (NCI) |
| Links | https://clinicaltrials.gov/ct2/show/NCT02828358 |
| Trial Status | Temporarily Closed |
| Trial Open Date | 27/03/2017 |
| Sites | Perth Children's Hospital |
| Study Type | Treatment |
| Phase | Phase 2 |
| Age Eligibility | up to 364 days |
| International registry ID's | NCT02828358 |